Compare Medpace Holdings Inc (MEDP) vs Mondaycom Ltd (MNDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Mondaycom Ltd — how do they compare? Medpace Holdings Inc trades at $611.57 (market cap $16.82B), while Mondaycom Ltd trades at $88.92 (market cap $3.76B). The key difference: Medpace Holdings Inc is far larger — about 4.5× Mondaycom Ltd's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Mondaycom Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Mondaycom Ltd for 16 Days on average.
| MEDP | MNDY | |
|---|---|---|
Market Cap | $16.82B | $3.76B |
Volume | 223,093 | 836,200 |
Sector | Health | Technology |
52-Week High | $630.19 | $205.24 |
52-Week Low | $393.42 | $58.81 |
Typical Hold Time | 14 Days | 16 Days |
Enterprise Value | $16.44B | $2.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
Monday.com (MNDY) trades at $88.41, up 5.87% in the last session, showing strong momentum near 52-week highs. The stock maintains a bullish technical outlook with consistent earnings beats and robust revenue growth. Recent Q2 2026 EPS of $1.48 exceeded expectations by 33%, while enterprise customer growth accelerated to 37% year-over-year. The company's Elevate '26 conference highlights AI integration efforts, positioning it for continued market share gains in the work management software sector.
With 65% analyst buy ratings and a $108.64 consensus price target, MNDY offers 23% upside potential. However, elevated valuation multiples (P/E 37.7, EV/EBITDA 53.5) and increasing competition from Meta's enterprise push present near-term risks. The stock's current RSI near 88 suggests overbought conditions, though fundamental growth drivers remain intact for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Mondaycom Ltd
Monday.com Ltd. is a cloud-based software company providing a Work OS (Operating System) that enables organizations to manage projects, processes, and daily work. The platform is highly customizable, enabling teams to build tailored applications and workflows for a range of use cases, from marketing and sales to software development and HR. monday.com serves clients across numerous industries, aiming to improve transparency, collaboration, and efficiency across the entire enterprise.
Read more on MNDY →
